Xolair 300 MG/2 ML syringe 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSKF9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,392
Award facts
- Contract value 100% obligated
- $11,392.44 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $11,392.44 to DMS Pharmaceutical Group Inc. for the supply of XOLAIR 300 mg/2 ml syringes. The award was issued on January 29, 2026, with an ultimate completion date of February 20, 2026, and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, was selected without a set-aside designation, demonstrating its competitive capability in unrestricted federal procurement. The company is headquartered in Park Ridge, Illinois, and has maintained registration in the System for Award Management since 2001.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.9 million contract awarded in November 2025 with a completion date of December 31, 2036. The PPV-G GEN V represents part of the broader $30.3 billion acquisition strategy designed to provide comprehensive pharmaceutical supply support to Department of Defense healthcare facilities worldwide. As an approved prime vendor contractor under this program, DMS Pharmaceutical Group is authorized to fulfill diverse pharmaceutical requirements, including branded and generic medications, biologics, and medical consumables for military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FSKF9?
SPE2DR26FSKF9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FSKF9 worth?
The government has obligated $11,392 on SPE2DR26FSKF9.
Is contract SPE2DR26FSKF9 an order under another contract?
Yes. SPE2DR26FSKF9 is a delivery order under SPE2DR25D9317, an indefinite delivery contract.
Was contract SPE2DR26FSKF9 competed?
The extent of competition for SPE2DR26FSKF9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award